Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

3SBio is a leading biopharmaceutical company in China. It is one of the earliest biologics innovators in the country, launching EPIAO in 1998 and TPIAO in 2005. The current portfolio is older ...

China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech ...

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.

The deal grants Pfizer rights to develop and commercialize a drug from Shenyang-based 3SBio Inc. currently in clinical testing for multiple tumor types, according to a press release. In addition ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...